Brexpiprazole CAS 913611-97-9 Raw Materials Powder

Related Attributes

Product details

Brexpiprazole Powder Usage and Synthesis.

Brexpiprazole Powder is a tricyclic antidepressant that is used to treat depression, obsessive-compulsive disorder, phobias, anorexia nervosa, and It increases the concentration of these neurotransmitters between neurons by blocking the reuptake of the It increases the concentration of these neurotransmitters between neurons by blocking the reuptake of the neurotransmitters norepinephrine and serotonin.

Brexpiprazole CAS 913611-97-9 is also used to treat nocturia and attention deficit hyperactivity disorder (ADHD). Brexpiprazole Raw Materials has been shown to be more effective in schizophrenia in terms of There is a trend toward better efficacy in negative symptoms and cognitive function, and a There is a trend toward better efficacy in negative symptoms and cognitive function, and a rapid onset of action when used as an adjunctive treatment for depression.

Application/Function of Brexpiprazole Powder.

Brexpiprazole Powder can be used as an adjunctive treatment for major depressive disorder, schizophrenia.
On July 10, 2015, the U.S. FDA approved Brexpiprazole, a new molecular entity for schizophrenia and depression from Otsuka, Japan, under the trade name Rexulti.
Brexpiprazole CAS 913611-97-9 oral formulation is an atypical antipsychotic, the specific mechanism of action is unknown, but experts analyze that it may work by partially activating pentraxin 5-HTIA receptors and dopamine D2 receptors, and blocking pentraxin 5-HT2A receptors.
Brexpiprazole Raw Materials can be used as an adjunctive drug in the treatment of adult patients with major depressive disorder; it can also be used in the treatment of adult patients with schizophrenia.

Production Method of Brexpiprazole Powder

Brexpiprazole is a modulator of 5-HT-dopamine receptor activity with partial agonism of 5-HT1A and dopamine D2 receptors and potent antagonism of 5-HT2A and norepinephrine α1B and α2C receptors. The agonistic effect of epipiprazole on D2 receptors is lower than that of aripiprazole and, therefore, its potential for sedentary inability is lower. Because of the weak affinity for histamine H1 receptors, it results in a lower sedative effect than other antipsychotics.

Major depressive disorder (MDD) is one of the most serious public health problems in the world, with a prevalence of about 4.7%. Although there are many antidepressant treatment options available, a large proportion of people do not respond to first-line treatment. In such cases, there is a need to switch to another antidepressant treatment regimen (a comparable drug) or to use an antidepressant booster (e.g., a second-generation antipsychotic).

Aripiprazole and quetiapine are currently approved for the adjunctive treatment of MDD, and olanzapine combined with fluoxetine is approved for the treatment of patients with refractory depression. Although effective, their use is limited by tolerability issues. For example, the inability to sedate with aripiprazole, the increased appetite/weight gain with the olanzapine-fluoxetine combination, and the sedative effects of quetiapine. Therefore, tolerability issues should be considered during treatment.

Why choose us?

HRK Factory

About Shipping